Literature DB >> 29026995

Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium.

Adebayo J Molehin1,2, Souad R Sennoune1,2, Weidong Zhang1,2, Juan U Rojo3, Arif J Siddiqui1,2, Karlie A Herrera1,2, Laura Johnson1,2, Justin Sudduth1,2, Jordan May1,2, Afzal A Siddiqui4,5.   

Abstract

Schistosomiasis remains a major global health problem. Despite large-scale schistosomiasis control efforts, clear limitations such as possible emergence of drug resistance and reinfection rates highlight the need for an effective schistosomiasis vaccine. Schistosoma mansoni large subunit of calpain (Sm-p80)-based vaccine formulations have shown remarkable efficacy in protecting against S. mansoni challenge infections in mice and baboons. In this study, we evaluated the cross-species protective efficacy of Sm-p80 vaccine against S. japonicum and S. haematobium challenge infections in rodent models. We also elucidated the expression of Sm-p80 and Sm-p80 ortholog proteins in different developmental stages of S. mansoni, S. haematobium, and S. japonicum. Immunization with Sm-p80 vaccine reduced worm burden by 46.75% against S. japonicum challenge infection in mice. DNA prime/protein boost (1 + 1 dose administered on a single day) resulted in 26.95% reduction in worm burden in S. haematobium-hamster infection/challenge model. A balanced Th1 (IFN-γ, TNF-α, IL-2, and IL-12) and Th2 (IL-4, IgG1) type of responses were observed following vaccination in both S. japonicum and S. haematobium challenge trials and these are associated with the prophylactic efficacy of Sm-p80 vaccine. Immunohistochemistry demonstrated that Sm-p80/Sm-p80 ortholog proteins are expressed in different life cycle stages of the three major human species of schistosomes studied. The data presented in this study reinforce the potential of Sm-p80-based vaccine for both hepatic/intestinal and urogenital schistosomiasis occurring in different geographical areas of the world. Differential expression of Sm-p80/Sm-p80 protein orthologs in different life cycle makes this vaccine potentially useful in targeting different levels of infection, disease, and transmission.

Entities:  

Keywords:  Cross-species protection; Schistosomiasis; Sm-p80 immunolocalization; Sm-p80 vaccine

Mesh:

Substances:

Year:  2017        PMID: 29026995      PMCID: PMC5660642          DOI: 10.1007/s00436-017-5634-4

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  71 in total

Review 1.  Immune responses to the radiation-attenuated schistosome vaccine: what can we learn from knock-out mice?

Authors:  R A Wilson; P S Coulson; A P Mountford
Journal:  Immunol Lett       Date:  1999-01       Impact factor: 3.685

2.  Proteins exposed at the adult schistosome surface revealed by biotinylation.

Authors:  Simon Braschi; R Alan Wilson
Journal:  Mol Cell Proteomics       Date:  2005-11-03       Impact factor: 5.911

3.  A statistically defined endpoint titer determination method for immunoassays.

Authors:  A Frey; J Di Canzio; D Zurakowski
Journal:  J Immunol Methods       Date:  1998-12-01       Impact factor: 2.303

4.  Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons.

Authors:  Souvik Karmakar; Weidong Zhang; Gul Ahmad; Workineh Torben; Mayeen U Alam; Loc Le; Raymond T Damian; Roman F Wolf; Gary L White; David W Carey; Darrick Carter; Steven G Reed; Afzal A Siddiqui
Journal:  Vaccine       Date:  2014-01-04       Impact factor: 3.641

5.  Histopathological observations in new and classic models of experimental Schistosoma haematobium infections.

Authors:  P N Vuong; C Bayssade-Dufour; J L Albaret; K Farhati
Journal:  Trop Med Int Health       Date:  1996-06       Impact factor: 2.622

Review 6.  Development of a schistosomiasis vaccine.

Authors:  Adebayo J Molehin; Juan U Rojo; Sabrina Z Siddiqui; Sean A Gray; Darrick Carter; Afzal A Siddiqui
Journal:  Expert Rev Vaccines       Date:  2016-01-13       Impact factor: 5.217

Review 7.  Immune effector mechanisms against schistosomiasis: looking for a chink in the parasite's armour.

Authors:  R Alan Wilson; Patricia S Coulson
Journal:  Trends Parasitol       Date:  2009-08-28

Review 8.  Controversies and challenges in research on urogenital schistosomiasis-associated bladder cancer.

Authors:  Jared Honeycutt; Olfat Hammam; Chi-Ling Fu; Michael H Hsieh
Journal:  Trends Parasitol       Date:  2014-06-06

9.  Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.

Authors:  Rhea N Coler; Sylvie Bertholet; Magdalini Moutaftsi; Jeff A Guderian; Hillarie Plessner Windish; Susan L Baldwin; Elsa M Laughlin; Malcolm S Duthie; Christopher B Fox; Darrick Carter; Martin Friede; Thomas S Vedvick; Steven G Reed
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

10.  A vaccine consisting of Schistosoma mansoni cathepsin B formulated in Montanide ISA 720 VG induces high level protection against murine schistosomiasis.

Authors:  Alessandra Ricciardi; Kittipos Visitsunthorn; John P Dalton; Momar Ndao
Journal:  BMC Infect Dis       Date:  2016-03-05       Impact factor: 3.090

View more
  9 in total

1.  Sm-p80-based schistosomiasis vaccine: double-blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission-blocking efficacy.

Authors:  Weidong Zhang; Adebayo J Molehin; Juan U Rojo; Justin Sudduth; Pramodh K Ganapathy; Eunjee Kim; Arif J Siddiqui; Jasmin Freeborn; Souad R Sennoune; Jordan May; Samra Lazarus; Catherine Nguyen; Whitni K Redman; Gul Ahmad; Workineh Torben; Souvik Karmakar; Loc Le; Kameswara R Kottapalli; Pratibha Kottapalli; Roman F Wolf; James F Papin; David Carey; Sean A Gray; Jenn D Bergthold; Raymond T Damian; Bryan T Mayer; Florian Marks; Steven G Reed; Darrick Carter; Afzal A Siddiqui
Journal:  Ann N Y Acad Sci       Date:  2018-08       Impact factor: 5.691

2.  Expression of CD117 (c-Kit) on Circulating B Cells in Pediatric Schistosomiasis.

Authors:  Isaac O Onkanga; Rachael Hamilton; Pauline N M Mwinzi; Thomas Schneider; Bartholomew N Ondigo; Huldah Sang; Edna Ondari; Fredrick Rawago; Walter Jaoko; Maurice R Odiere; Lisa Ganley-Leal
Journal:  Infect Immun       Date:  2022-07-06       Impact factor: 3.609

3.  Fifteen Years of Sm-p80-Based Vaccine Trials in Nonhuman Primates: Antibodies From Vaccinated Baboons Confer Protection in vivo and in vitro From Schistosoma mansoni and Identification of Putative Correlative Markers of Protection.

Authors:  Weidong Zhang; Loc Le; Gul Ahmad; Adebayo J Molehin; Arif J Siddiqui; Workineh Torben; Souvik Karmakar; Juan U Rojo; Souad Sennoune; Samara Lazarus; Sabiha Khatoon; Jasmin Freeborn; Justin Sudduth; Ashraf F Rezk; David Carey; Roman F Wolf; James F Papin; Ray Damian; Sean A Gray; Florian Marks; Darrick Carter; Afzal A Siddiqui
Journal:  Front Immunol       Date:  2020-06-19       Impact factor: 7.561

4.  A comparative analysis of secreted protein disulfide isomerases from the tropical co-endemic parasites Schistosoma mansoni and Leishmania major.

Authors:  Adriana E Miele; Sofiane Badaoui; Lorenzo Maugliani; Romain Salza; Giovanna Boumis; Silvia Chichiarelli; Bertrand Duclos; Sylvie Ricard-Blum
Journal:  Sci Rep       Date:  2019-07-02       Impact factor: 4.379

5.  Process Development of Sj-p80: A Low-Cost Transmission-Blocking Veterinary Vaccine for Asiatic Schistosomiasis.

Authors:  Adebayo J Molehin; Sean A Gray; Cheri Turner; Jennifer Davis; Weidong Zhang; Sabiha Khatoon; Madison Rattan; Rebecca Kernen; Christopher Peterson; Souad R Sennoune; Darrick Carter; Afzal A Siddiqui
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

Review 6.  Vaccines for Human Schistosomiasis: Recent Progress, New Developments and Future Prospects.

Authors:  Adebayo J Molehin; Donald P McManus; Hong You
Journal:  Int J Mol Sci       Date:  2022-02-18       Impact factor: 5.923

7.  A low dose adenovirus vectored vaccine expressing Schistosoma mansoni Cathepsin B protects from intestinal schistosomiasis in mice.

Authors:  Dilhan J Perera; Adam S Hassan; Sunny S Liu; Seyyed Mehdy Elahi; Christine Gadoury; Risini D Weeratna; Rénald Gilbert; Momar Ndao
Journal:  EBioMedicine       Date:  2022-04-30       Impact factor: 11.205

8.  Schistosoma mansoni antigen Sm-p80: prophylactic efficacy using TLR4 agonist vaccine adjuvant glucopyranosyl lipid A-Alum in murine and non-human primate models.

Authors:  Weidong Zhang; Gul Ahmad; Adebayo J Molehin; Workineh Torben; Loc Le; Eunjee Kim; Samra Lazarus; Arif J Siddiqui; Darrick Carter; Afzal A Siddiqui
Journal:  J Investig Med       Date:  2018-07-10       Impact factor: 2.895

Review 9.  Schistosomiasis vaccine development: update on human clinical trials.

Authors:  Adebayo J Molehin
Journal:  J Biomed Sci       Date:  2020-01-22       Impact factor: 8.410

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.